Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer

NCT05205200 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05205200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05205200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
June 6, 2022
Completion date
August 1, 2026
Enrollment
338 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic cancer